EMBRACA

NCT01945775 📎

Regimen

Experimental
Talazoparib 1 mg once daily orally until progression.
Control
Physician's choice single-agent chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).

Population

HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2 pathogenic variant; up to 3 prior cytotoxic regimens permitted.

Key finding

EMBRACA established talazoparib as second PARP inhibitor option in germline BRCA-mutated HER2-negative advanced breast cancer (FDA approved October 2018). PFS benefit similar magnitude to OlympiAD; OS not significant.

Source: PMID 30110579

Timeline

  • Publication: 2018 Aug 23

Guideline citations

  • NCCN BREAST